Oppenheimer upped their price target on Moderna (NASDAQ: MRNA) after the US drugmaker recently saw its respiratory syncytial virus (RSV) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE